Pharming Group (PHAR) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is PHAR's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Pharming to participate in fireside chat at Jefferies Global Healthcare Conference in London on Wednesday Nov. 18 at 9:30 am GMT. Webcast will be available…

MHRA approves Pharming's Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K. Approval extends existing U.K. indication.…

A rare-disease player with a stabilized core product is now targeting a market 26 times larger, fueled by cash generation that needs no external financing.…

Pharming Group N.V. ( PHAR ) Q3 2026 Earnings Call October 27, 2026 8:30 AM EDT Company Participants Kenneth Lynard - CFO & Co-Chief Executive Officer Leverne Marsh - Co-CEO & Chief Commercial Officer Anurag Relan - Chie…

Pharming Group NASDAQ: PHAR reported third-quarter revenue growth of 21% to $117.6 million, supported by higher sales of its RUCONEST hereditary angioedema treatment and Joenja therapy for activated phosphoinositide 3-ki…

Third quarter 2026 total revenues increased by 21% to US$117.6 million, compared to third quarter 2025, exceeding market expectations RUCONEST® revenue increased by 14% to US$93.8 million, compared to third quarter 2025,…

Third quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025 Third quarter 2026 total operating expenses of approximately US$74.6 million, in line with third quarter…

First clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulation Leniolisib was well-tolerated, with benefits obs…

RUCONEST is Pharming Group's main revenue source today. This asset has already shown a sequential sales rebound that makes me more optimistic. However, RUCONEST still has oral competition that could make stabilizing that…

Leiden, the Netherlands, September 29, 2026 : Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the Board of Directors and…

If approved, J oenja would be available to eligible patients aged 4 years and older with APDS who weigh 13 kg or more Decision follows recent approval of Joenja for children aged 4 to 11 years with APDS weighing at least…

Leniolisib was generally well-tolerated, with clinical improvements across multiple measures of immune dysregulation, including reductions in lymphoproliferation Separately, Pharming expects to report topline results fro…

MAC Alpha Capital Management LP acquired a new position in Pharming Group N.V. Sponsored ADR (NASDAQ: PHAR) during a recent quarter, according to the company in its most recent disclosure with the Securities and Exchange…

FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 who weigh at least 27kg Newly approved Joenja doses are expected to be availa…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

